Indefinite Delivery Contract SPE2DR25D9158

DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was awarded a single-award Indefinite Delivery Contract (IDC) valued at $5.0 million by the Defense Logistics Agency (DLA) on August 1, 2025, with an ultimate completion date of December 31, 2036. The contract, designated SPE2DX under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, authorizes DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide. The contract scope encompasses branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables, including oncology treatments (Keytruda, Tecentriq, Xtandi), immunosuppressants (Nucala, Xolair, Stelara, HEMLIBRA), emergency medications (epinephrine auto-injectors, naloxone), specialty surgical products (EXPAREL, MACI implants), contraceptive devices (Mirena systems), vaccines, and routine pharmaceuticals spanning antibiotics, antivirals, pain management drugs, and supportive care products. No set-aside was used in this procurement.

The underlying solicitation, issued as a pre-solicitation notice on February 1, 2024, established the Pharmaceutical Prime Vendor Global Program Generation V as part of the Department of Defense's broader acquisition strategy valued at $30.3 billion total. The solicitation contemplated multiple awards on a regional basis to establish separate pharmaceutical supply contracts for North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet customers, with each contract structured as a 30-month base period plus three 30-month option periods. Awards were to be made to responsive and responsible offerors whose proposals were technically acceptable and offered the lowest overall price based on distribution fees, with both primary and backup suppliers designated to provide separate distribution fees for brand/generic and specialty pharmaceuticals to support normal and contingency operations globally. DMS Pharmaceutical Group's contract positions the company as a critical pharmaceutical supplier within the federal military medical supply chain, leveraging its established small business status and demonstrated performance on numerous delivery orders to fulfill the diverse and specialized pharmaceutical requirements of Department of Defense healthcare operations.